AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...
Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...
Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the ...
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...
Serna Bio, an AI drug discovery company pioneering RNA-targeting small molecules, today announced the members of its Scientific Advisory Board (SAB). Established in 2021, Serna Bio is a preclinical ...
Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback